FROM THE PUBLISHER
Since Alois Alzheimer described the results of his postmortem studies in 1906,
significant strides have been made in understanding the pathogenesis of
neurodegenerative diseases. Substantial evidence has accumulated indicating that
diverse neurodegenerative disorders might share a common pathological mechanism:
the misfolding, aggregation and accumulation of proteins (termed "amyloid") in
the brain. Metal ions have long been thought to catalyze protein misfolding
initiating a cascade of events resulting in oxidative damage and
neurodegeneration. They have, consequently, been seen as a suitable
pharmacological target. However, drugs aimed at simply removing excess metals or
interfering in amyloid deposition were unsuccessful and scientists have been
forced to review the classical hypothesis.